FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893845410> ?p ?o ?g. }

• W2893845410 endingPage "421" @default.
• W2893845410 startingPage "412" @default.
• W2893845410 abstract "PAR2 has been proposed to contribute to lesion formation and intense itch in atopic dermatitis. Here, we tested the ability of a cell-penetrating pepducin, PZ-235, to mitigate the potentially deleterious effects of PAR2 in models of atopic dermatitis. PZ-235 significantly inhibited PAR2-mediated expression of inflammatory factors NF-κB, TSLP, TNF-α, and differentiation marker K10 by 94%–98% (P < 0.001) in human keratinocytes and suppressed IL-4 and IL-13 by 68%–83% (P < 0.05) in mast cells. In delayed pepducin treatment models of oxazolone- and DNFB-induced dermatitis, PZ-235 significantly attenuated skin thickening by 43%–100% (P < 0.01) and leukocyte crusting by 57% (P < 0.05), and it inhibited ex vivo chemotaxis of leukocytes toward PAR2 agonists. Daily PZ-235 treatment of filaggrin-deficient mice exposed to dust mite allergens for 8 weeks significantly suppressed total leukocyte and T-cell infiltration by 50%–68%; epidermal thickness by 60%–77%; and skin thickening, scaling, excoriation, and total lesion severity score by 46%–56%. PZ-235 significantly reduced itching caused by wasp venom peptide degranulation of mast cells in mice by 51% (P < 0.05), which was comparable to the protective effects conferred by PAR2 deficiency. Taken together, these results suggest that a PAR2 pepducin may confer broad therapeutic benefits as a disease-modifying treatment for atopic dermatitis and itch. PAR2 has been proposed to contribute to lesion formation and intense itch in atopic dermatitis. Here, we tested the ability of a cell-penetrating pepducin, PZ-235, to mitigate the potentially deleterious effects of PAR2 in models of atopic dermatitis. PZ-235 significantly inhibited PAR2-mediated expression of inflammatory factors NF-κB, TSLP, TNF-α, and differentiation marker K10 by 94%–98% (P < 0.001) in human keratinocytes and suppressed IL-4 and IL-13 by 68%–83% (P < 0.05) in mast cells. In delayed pepducin treatment models of oxazolone- and DNFB-induced dermatitis, PZ-235 significantly attenuated skin thickening by 43%–100% (P < 0.01) and leukocyte crusting by 57% (P < 0.05), and it inhibited ex vivo chemotaxis of leukocytes toward PAR2 agonists. Daily PZ-235 treatment of filaggrin-deficient mice exposed to dust mite allergens for 8 weeks significantly suppressed total leukocyte and T-cell infiltration by 50%–68%; epidermal thickness by 60%–77%; and skin thickening, scaling, excoriation, and total lesion severity score by 46%–56%. PZ-235 significantly reduced itching caused by wasp venom peptide degranulation of mast cells in mice by 51% (P < 0.05), which was comparable to the protective effects conferred by PAR2 deficiency. Taken together, these results suggest that a PAR2 pepducin may confer broad therapeutic benefits as a disease-modifying treatment for atopic dermatitis and itch." @default.
• W2893845410 created "2018-10-05" @default.
• W2893845410 creator A5002204355 @default.
• W2893845410 creator A5003639146 @default.
• W2893845410 creator A5003792680 @default.
• W2893845410 creator A5006545278 @default.
• W2893845410 creator A5026942701 @default.
• W2893845410 creator A5030482050 @default.
• W2893845410 creator A5077617262 @default.
• W2893845410 creator A5079811190 @default.
• W2893845410 creator A5081535211 @default.
• W2893845410 date "2019-02-01" @default.
• W2893845410 modified "2023-10-17" @default.
• W2893845410 title "PAR2 Pepducin-Based Suppression of Inflammation and Itch in Atopic Dermatitis Models" @default.
• W2893845410 cites W1585076901 @default.
• W2893845410 cites W1812613913 @default.
• W2893845410 cites W1827703464 @default.
• W2893845410 cites W1864146476 @default.
• W2893845410 cites W1966538694 @default.
• W2893845410 cites W1969969289 @default.
• W2893845410 cites W1971260504 @default.
• W2893845410 cites W1972857819 @default.
• W2893845410 cites W1975965422 @default.
• W2893845410 cites W1979230562 @default.
• W2893845410 cites W1983218074 @default.
• W2893845410 cites W1986892770 @default.
• W2893845410 cites W1989941487 @default.
• W2893845410 cites W1991202990 @default.
• W2893845410 cites W1993874766 @default.
• W2893845410 cites W1999174354 @default.
• W2893845410 cites W2010739774 @default.
• W2893845410 cites W2020745012 @default.
• W2893845410 cites W2035532961 @default.
• W2893845410 cites W2036487194 @default.
• W2893845410 cites W2039603982 @default.
• W2893845410 cites W2055580813 @default.
• W2893845410 cites W2063903492 @default.
• W2893845410 cites W2064016804 @default.
• W2893845410 cites W2065612614 @default.
• W2893845410 cites W2066693617 @default.
• W2893845410 cites W2067856993 @default.
• W2893845410 cites W2074543913 @default.
• W2893845410 cites W2076131500 @default.
• W2893845410 cites W2076606084 @default.
• W2893845410 cites W2088500273 @default.
• W2893845410 cites W2088627901 @default.
• W2893845410 cites W2096872877 @default.
• W2893845410 cites W2105643257 @default.
• W2893845410 cites W2109909774 @default.
• W2893845410 cites W2111281304 @default.
• W2893845410 cites W2112771128 @default.
• W2893845410 cites W2118630839 @default.
• W2893845410 cites W2131309533 @default.
• W2893845410 cites W2133543836 @default.
• W2893845410 cites W2140264128 @default.
• W2893845410 cites W2144344238 @default.
• W2893845410 cites W2146263464 @default.
• W2893845410 cites W2146302565 @default.
• W2893845410 cites W2146641981 @default.
• W2893845410 cites W2147746949 @default.
• W2893845410 cites W2152201554 @default.
• W2893845410 cites W2158259619 @default.
• W2893845410 cites W2161939173 @default.
• W2893845410 cites W2169100849 @default.
• W2893845410 cites W2204048255 @default.
• W2893845410 cites W2512890504 @default.
• W2893845410 cites W2604782609 @default.
• W2893845410 cites W2771862195 @default.
• W2893845410 cites W2787910333 @default.
• W2893845410 doi "https://doi.org/10.1016/j.jid.2018.08.019" @default.
• W2893845410 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6830517" @default.
• W2893845410 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30287285" @default.
• W2893845410 hasPublicationYear "2019" @default.
• W2893845410 type Work @default.
• W2893845410 sameAs 2893845410 @default.
• W2893845410 citedByCount "45" @default.
• W2893845410 countsByYear W28938454102019 @default.
• W2893845410 countsByYear W28938454102020 @default.
• W2893845410 countsByYear W28938454102021 @default.
• W2893845410 countsByYear W28938454102022 @default.
• W2893845410 countsByYear W28938454102023 @default.
• W2893845410 crossrefType "journal-article" @default.
• W2893845410 hasAuthorship W2893845410A5002204355 @default.
• W2893845410 hasAuthorship W2893845410A5003639146 @default.
• W2893845410 hasAuthorship W2893845410A5003792680 @default.
• W2893845410 hasAuthorship W2893845410A5006545278 @default.
• W2893845410 hasAuthorship W2893845410A5026942701 @default.
• W2893845410 hasAuthorship W2893845410A5030482050 @default.
• W2893845410 hasAuthorship W2893845410A5077617262 @default.
• W2893845410 hasAuthorship W2893845410A5079811190 @default.
• W2893845410 hasAuthorship W2893845410A5081535211 @default.
• W2893845410 hasBestOaLocation W28938454101 @default.
• W2893845410 hasConcept C126322002 @default.
• W2893845410 hasConcept C142724271 @default.
• W2893845410 hasConcept C16005928 @default.
• W2893845410 hasConcept C170493617 @default.
• W2893845410 hasConcept C190684412 @default.
• W2893845410 hasConcept C203014093 @default.

• next